Janux Therapeutics Inc. (JANX)
NASDAQ: JANX
· Real-Time Price · USD
22.02
0.25 (1.15%)
At close: Sep 26, 2025, 11:05 AM
1.15% (1D)
| Bid | 21.98 |
| Market Cap | 1.32B |
| Revenue (ttm) | -8.07M |
| Net Income (ttm) | -105.64M |
| EPS (ttm) | -1.72 |
| PE Ratio (ttm) | -12.8 |
| Forward PE | -7.59 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 22.02 |
| Volume | 93,492 |
| Avg. Volume (20D) | 800,468 |
| Open | 22.00 |
| Previous Close | 21.77 |
| Day's Range | 21.83 - 22.32 |
| 52-Week Range | 21.73 - 71.71 |
| Beta | 2.84 |
| Ex-Dividend Date | n/a |
About JANX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol JANX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for JANX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsJanux Therapeutics Inc. is scheduled to release its earnings on
Nov 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
9 months ago
+11.64%
Janux Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
9 months ago
+48.98%
Janux Therapeutics shares are trading higher after the company announced updated interim clinical data for its JANX007 program in prostate cancer.
1 month ago · https://thefly.com
Piper starts Janux Therapeutics with an Overweight on 'best-in-class' potentialAs previously reported, Piper Sandler initiated coverage of Janux Therapeutics with an Overweight rating and $42 price target. While noting that investor sentiment has waned over the course of 2025 fo...
